Medical affairs teams produce evidence-based, non-promotional scientific content for healthcare professionals (HCPs), while ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

For example, if they are trained on data that reflects existing disparities in treatment or demographics, the AI could perpetuate these inequalities, leading to poorer patient outcomes. To guard ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

At Reuters Pharma USA last month, Editor in Chief Jonah Comstock caught up with John Androsavich, general manager of Gingko ...

Chris Molloy, CEO of the Medicines Discovery Catapult, one of the latest members of the UK’s Catapult network, explains why SMEs are set to power future medicines development. We are familiar ...

In the pharmaceutical and cosmetic sectors, innovation often stems from discovering new applications for known compounds. In these situations, an innovator cannot patent the compound itself ...

Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clinical bottlenecks ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry stakeholders, including governments, public health bodies, and regulatory agencies - to ...